Patient acquisition for ketamine therapy starts with a site that actually explains what you do. We build for the IV-vs-Spravato distinction, the ad policies, and the patient comparing five clinics before they pick up the phone.
Ketamine therapy sits where FDA regulation, DEA scheduling, state medical boards, and ad-platform policy all overlap. IV ketamine infusion is administered off-label for treatment-resistant depression, chronic pain, and PTSD. Spravato (esketamine) is FDA-approved but governed by a REMS program that dictates who can prescribe it and where. Your site has to hold that distinction precisely — because patients are confused by it, Google's pharmaceutical ad policy enforces it, and state boards have opinions about how you word it. Add the comparison-shopping reality: most ketamine sites look identical — the same recliner stock photo, the same vague "new hope for depression." Patients open five tabs before they call. If yours doesn't answer their real questions about protocols, providers, and pricing, they move on. State-by-state disclaimers, condition-first education, and ad-safe content aren't add-ons here. They're the build.
Treatment tracks, provider authority, compliant acquisition, and intake — assembled for the regulatory and competitive reality of this space.
Separate, medically reviewed pages for IV ketamine infusion (off-label) and Spravato (esketamine) under REMS — plus condition pages for TRD, PTSD, chronic pain, OCD, and anxiety that answer the questions patients actually search.
Credential-forward provider pages — board certification, training, protocol transparency — marked up with Physician schema so they earn rich snippets and signal clinical authority for a Schedule III decision.
What-to-expect walkthroughs, IV-vs-Spravato-vs-oral comparisons, and pricing and insurance transparency. The content that wins the patient already comparison-shopping five other clinics.
Policy-safe landing pages and ad copy built around treatment-condition keywords, not substance terms — engineered to pass Google's pharmaceutical review instead of tripping automated disapproval.
Location-aware architecture for multi-site groups: unique local pages, Google Business Profile alignment, LocalBusiness schema, and consistent NAP that ranks each market independently.
Encrypted, HIPAA-compliant intake — PHQ-9 and GAD-7 screening, insurance verification steps, audit-trailed request forms, and click-to-call tracking mapped to marketing source, with no PHI exposed.
Post-treatment review request automation, Google Business Profile strategy, and Review schema for search visibility — with testimonial anonymization and consent built into the process.
Disclaimer components that adapt to your operating states: telehealth prescribing rules, in-person evaluation requirements, and administration restrictions, wired into the CMS so nothing unqualified ships.
Organic search is your most reliable channel because it isn't bound by the ad restrictions that kill paid ketamine campaigns. We lead with condition-first SEO and back it with ad variants that survive review.
Condition-keyword campaigns that dodge substance triggers. LegitScript support for ad-account reinstatement. Physician-authored E-E-A-T content and FAQ pages built for featured snippets. We've run this under pressure — rebuilding Klarity Clinic from a catastrophic deletion with no backups taught us exactly what ketamine marketing needs when there's no safety net.
Broader behavioral health practice →Ketamine therapy sits in a regulatory gray area that general web agencies don't understand. Your site needs to clearly differentiate between FDA-approved Spravato (esketamine) and off-label IV ketamine infusions, include proper medical disclaimers by state, avoid claims that trigger Google Ads disapprovals, and educate patients who are often comparing you against dozens of other providers. A generic healthcare template won't handle any of that correctly.
Yes, but with significant restrictions. Google classifies ketamine under its pharmaceutical advertising policies, which means you cannot bid on certain terms directly. We build compliant landing page variants and ad copy that pass Google's review process, focusing on treatment-condition keywords like "treatment resistant depression therapy" rather than substance-specific terms. Spravato providers with REMS certification have slightly more flexibility in ad copy, and we structure campaigns to take advantage of that where applicable.
Spravato (esketamine) is FDA-approved and administered under REMS, which gives providers a compliance framework to reference in marketing materials. IV ketamine infusion is used off-label, so marketing claims need to be more carefully worded to avoid implying FDA approval for specific conditions. The content strategy, disclaimer language, and ad policies differ substantially between the two. We build separate content tracks for clinics that offer both.
A full ketamine clinic website with treatment pages, provider bios, patient education content, intake workflows, and compliance review typically takes 6 to 10 weeks. That includes information architecture, content development, legal and compliance review of all claims, and performance optimization. Clinics that need LegitScript certification support or multi-location SEO architecture should plan for the longer end of that range.
A ketamine site converts better when intake, verification, and routing are built in — every handoff designed so nothing leaks between tools.
AI intake that talks like your sharpest admissions counselor — runs criteria, captures insurance, and routes qualified patients 24/7.
Explore Cadence → VerifyReal-time verification of benefits, matched against the thresholds your clinic configures.
Explore Verafide → CaptureHIPAA-compliant intake forms for visitors who'd rather type than talk.
RouteReceives every qualified inquiry with full context and payer-aware scoring.
OrchestrateRuns the stack across every location from one control plane.
We'll scope the project, map the compliance landscape for your operating states, and return a build plan with timelines and benchmarks.